USD 9.09
(0.39%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 85.1 Million USD | -31.09% |
2022 | 122.9 Million USD | -6.85% |
2021 | 131.95 Million USD | 2.43% |
2020 | 128.81 Million USD | 3.1% |
2019 | 124.93 Million USD | 18.18% |
2018 | 105.71 Million USD | 117.84% |
2017 | 48.53 Million USD | 126.22% |
2016 | 21.45 Million USD | -22.04% |
2015 | 27.51 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 21.64 Million USD | 7.53% |
2024 Q2 | 24.97 Million USD | 15.78% |
2023 Q3 | 19.29 Million USD | -8.37% |
2023 Q4 | 20.12 Million USD | 4.32% |
2023 Q2 | 21.05 Million USD | -14.09% |
2023 FY | 84.7 Million USD | -31.09% |
2023 Q1 | 24.5 Million USD | -6.57% |
2022 Q4 | 26.23 Million USD | -8.77% |
2022 Q3 | 28.75 Million USD | -14.89% |
2022 Q2 | 33.78 Million USD | -1.05% |
2022 Q1 | 34.14 Million USD | 8.03% |
2022 FY | 122.9 Million USD | -6.85% |
2021 Q3 | 32.45 Million USD | -8.54% |
2021 Q2 | 35.48 Million USD | 9.5% |
2021 Q1 | 32.4 Million USD | -6.21% |
2021 FY | 131.95 Million USD | 2.43% |
2021 Q4 | 31.6 Million USD | -2.63% |
2020 Q4 | 34.55 Million USD | 11.11% |
2020 Q2 | 31.17 Million USD | -2.57% |
2020 Q3 | 31.09 Million USD | -0.23% |
2020 FY | 128.81 Million USD | 3.1% |
2020 Q1 | 31.99 Million USD | 0.21% |
2019 FY | 124.93 Million USD | 18.18% |
2019 Q2 | 31.29 Million USD | 1.27% |
2019 Q1 | 30.9 Million USD | 14.35% |
2019 Q4 | 31.92 Million USD | 3.59% |
2019 Q3 | 30.81 Million USD | -1.53% |
2018 Q1 | 29.52 Million USD | 49.89% |
2018 FY | 105.71 Million USD | 117.84% |
2018 Q4 | 27.02 Million USD | 7.95% |
2018 Q3 | 25.03 Million USD | 5.35% |
2018 Q2 | 23.76 Million USD | -19.52% |
2017 Q1 | 7.25 Million USD | 54.64% |
2017 Q2 | 8.29 Million USD | 14.32% |
2017 Q3 | 13.16 Million USD | 58.74% |
2017 Q4 | 19.69 Million USD | 49.62% |
2017 FY | 48.53 Million USD | 126.22% |
2016 FY | 21.45 Million USD | -22.04% |
2016 Q2 | 4.43 Million USD | -37.47% |
2016 Q3 | 5.25 Million USD | 18.69% |
2016 Q4 | 4.69 Million USD | -10.8% |
2016 Q1 | 7.08 Million USD | 0.0% |
2015 FY | 27.51 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Bright Green Corporation | 8.25 Million USD | -931.18% |
Alpha Teknova, Inc. | 45.85 Million USD | -85.573% |
ANI Pharmaceuticals, Inc. | 195.98 Million USD | 56.577% |
Aquestive Therapeutics, Inc. | 44.85 Million USD | -89.731% |
Collegium Pharmaceutical, Inc. | 159.2 Million USD | 46.547% |
Cosmos Health Inc. | 26.18 Million USD | -225.055% |
Journey Medical Corporation | 54.59 Million USD | -55.882% |
Embecta Corp. | 528.4 Million USD | 83.894% |
Esperion Therapeutics, Inc. | 271.89 Million USD | 68.701% |
Dynavax Technologies Corporation | 219.14 Million USD | 61.166% |
Intra-Cellular Therapies, Inc. | 590 Million USD | 85.576% |
Pacira BioSciences, Inc. | 326.37 Million USD | 73.925% |
PainReform Ltd. | 9.58 Million USD | -787.959% |
Sunshine Biopharma, Inc. | 13.12 Million USD | -548.422% |
Sunshine Biopharma, Inc. | 13.12 Million USD | -548.422% |
SCYNEXIS, Inc. | 51.84 Million USD | -64.137% |
Safety Shot Inc | 12.1 Million USD | -602.759% |
China SXT Pharmaceuticals, Inc. | 3.06 Million USD | -2672.786% |
Procaps Group, S.A. | 199.47 Million USD | 57.337% |
Theratechnologies Inc. | 72.75 Million USD | -16.969% |
Harrow Health, Inc. | 89.97 Million USD | 5.414% |
Sonoma Pharmaceuticals, Inc. | 9.44 Million USD | -800.932% |
Biofrontera Inc. | 39.95 Million USD | -112.973% |
DURECT Corporation | 43.71 Million USD | -94.675% |
Supernus Pharmaceuticals, Inc. | 529.01 Million USD | 83.913% |
Cronos Group Inc. | 96.7 Million USD | 12.002% |
Ironwood Pharmaceuticals, Inc. | 232.12 Million USD | 63.338% |
Kala Pharmaceuticals, Inc. | 39.15 Million USD | -117.358% |
RedHill Biopharma Ltd. | -9.56 Million USD | 990.095% |
Organogenesis Holdings Inc. | 314.13 Million USD | 72.909% |
Guardion Health Sciences, Inc. | 9.73 Million USD | -774.56% |
Cumberland Pharmaceuticals Inc. | 43.04 Million USD | -97.725% |
Radius Health, Inc. | 265.92 Million USD | 67.998% |
Universe Pharmaceuticals INC | 13.84 Million USD | -514.814% |
ProPhase Labs, Inc. | 37.85 Million USD | -124.828% |
Phibro Animal Health Corporation | 260.29 Million USD | 67.306% |
Procaps Group S.A. | 187.24 Million USD | 54.55% |
Alvotech | 285.43 Million USD | 70.185% |
TherapeuticsMD, Inc. | 9.82 Million USD | -766.178% |
Viatris Inc. | 5.96 Billion USD | 98.574% |
Rockwell Medical, Inc. | 15.37 Million USD | -453.545% |
Aytu BioPharma, Inc. | 59.84 Million USD | -42.216% |
SIGA Technologies, Inc. | 22.04 Million USD | -286.072% |
Tilray Brands, Inc. | 251.35 Million USD | 66.143% |
Lifecore Biomedical, Inc. | 49.03 Million USD | -73.543% |
Shineco, Inc. | 17.94 Million USD | -374.158% |
PetIQ, Inc. | 192.72 Million USD | 55.843% |
Regencell Bioscience Holdings Limited | 3.99 Million USD | -2032.274% |
Incannex Healthcare Limited | 30.05 Million USD | -183.173% |
Neurocrine Biosciences, Inc. | 1.59 Billion USD | 94.669% |
Alimera Sciences, Inc. | 62.64 Million USD | -35.857% |
Silver Spike Investment Corp. | 762.49 Thousand USD | -11061.035% |
Assertio Holdings, Inc. | 368.58 Million USD | 76.911% |
Shuttle Pharmaceuticals Holdings, Inc. | 5.88 Million USD | -1345.943% |
Petros Pharmaceuticals, Inc. | 17.8 Million USD | -377.872% |
Clever Leaves Holdings Inc. | 21.16 Million USD | -302.012% |
Cyclo Therapeutics, Inc. | 21.04 Million USD | -304.437% |
Avadel Pharmaceuticals plc | 164.96 Million USD | 48.412% |
Hempacco Co., Inc. | 7.59 Million USD | -1020.287% |
Talphera, Inc. | 11.99 Million USD | -609.538% |
Alvotech | 285.43 Million USD | 70.185% |
Eagle Pharmaceuticals, Inc. | 140.71 Million USD | 39.521% |
Lantheus Holdings, Inc. | 344.9 Million USD | 75.326% |
Currenc Group, Inc. | 24 Million USD | -254.561% |
Kamada Ltd. | 45.42 Million USD | -87.342% |
Indivior PLC | 911 Million USD | 90.658% |
Evoke Pharma, Inc. | 12.4 Million USD | -585.773% |
Flora Growth Corp. | 10.57 Million USD | -704.443% |
Cyclo Therapeutics, Inc. | 21.04 Million USD | -304.437% |
Evolus, Inc. | 189.75 Million USD | 55.153% |
HUTCHMED (China) Limited | 436.23 Million USD | 80.492% |
Amphastar Pharmaceuticals, Inc. | 154.13 Million USD | 44.787% |
Akanda Corp. | 3.48 Million USD | -2342.997% |